Ongoing Study of Elacestrant + Targeted Therapy: ELEVATE
Panelists discuss the ELEVATE trial’s ongoing evaluation of lasofoxifene combined with targeted agents such as ribociclib, capivasertib, and everolimus, emphasizing the importance of optimizing dosing—such as the ribociclib reduction to 400 mg on a 3-weeks …